HMGN.US Hemagen Diagnostics Inc
- Market cap
- USD 3.10K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Sep 2012.
Is HMGN.US undervalued?
Graham numberThe Graham number of Hemagen Diagnostics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hemagen Diagnostics Inc fundamental analysis
No fundamental analysis for Hemagen Diagnostics Inc yet.
Hemagen Diagnostics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hemagen Diagnostics Inc
Hemagen Diagnostics, Inc. provides human and veterinary diagnostic services worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its proprietary test kits are used to aid in the diagnosis of certain autoimmune and infectious diseases. It also provides human diagnostics, such as universal IFA components; supplies, controls and calibr…
Full company profileHemagen Diagnostics Inc financial statements
Hemagen Diagnostics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 8.47M | 7.47M | 7.59M | 4.78M | 4.49M | 6.37M | 5.42M | 5.22M | 5.14M | 4.04M |
| Gross Profit | 2.99M | 2.15M | 1.91M | 1.90M | 1.88M | 2.77M | 2.07M | 2.36M | 1.96M | 1.61M |
| Operating Income | 245K | -569K | -875K | -165K | -159K | 118K | -349K | 236K | -473K | -438K |
| EBITDA | 1.89M | 1.66M | -359K | -65.4K | -57.1K | 226K | -192K | 429K | -284K | -274K |
| Net Income | -1.27M | -3.60M | -1.34M | 313K | -850K | 427K | -808K | -156K | -880K | -907K |
| EPS | -0.13 | -0.36 | -0.09 | 0.02 | -0.06 | 0.03 | -0.05 | -0.01 | -0.06 | -0.06 |
| Balance Sheet | ||||||||||
| Total Assets | 6.49M | 5.63M | 5.34M | 4.39M | 4.14M | 4.77M | 3.72M | 3.37M | 2.89M | 2.44M |
| Total Liabilities | 4.56M | 5.36M | 6.36M | 5.10M | 5.63M | 5.86M | 5.50M | 5.22M | 5.58M | 6.00M |
| Shareholders' Equity | 1.92M | 262K | -1.02M | -708K | -1.50M | -1.09M | -1.78M | -1.85M | -2.69M | -3.56M |
| Cash & Short-term Investments | 724K | 539K | 272K | 151K | 6.59K | 98.8K | 156K | 152K | 214K | 66.3K |
| Total Debt | 3.11M | 3.73M | 4.84M | 3.84M | 4.28M | 4.63M | 4.48M | 4.45M | 4.72M | 5.03M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 459K | -166K | -475K | -737K | -482K | 265K | 16.8K | -183K | -337K | -359K |
| Capital Expenditure | 9.31K | 38.7K | 851K | 19.7K | 85.9K | 368K | 115K | 74.1K | 56.4K | 91.0K |
| Free Cash Flow | 450K | -204K | -1.33M | -757K | -568K | -103K | -98.1K | -257K | -394K | -450K |
| Ratios | ||||||||||
| ROE | -65.8% | -1,373.9% | - | - | - | - | - | - | - | - |
| ROA | -19.5% | -64.0% | -25.1% | 7.1% | -20.6% | 9.0% | -21.7% | -4.6% | -30.5% | -37.1% |
| Net Profit Margin | -14.9% | -48.2% | -17.6% | 6.6% | -18.9% | 6.7% | -14.9% | -3.0% | -17.1% | -22.4% |
| Debt to Equity | 1.62x | 14.22x | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hemagen Diagnostics Inc dividends
Hemagen Diagnostics Inc has not paid dividends in the last 10 fiscal years.
Who owns Hemagen Diagnostics Inc
Ownership data of Hemagen Diagnostics Inc is not available yet.
Hemagen Diagnostics Inc company profile
- Company name
- Hemagen Diagnostics Inc
- Ticker
- HMGN.US
- Exchange
- USA Stocks
- Listed since
- Feb 4, 1993
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 15
- Fiscal year end
- September
- Address
- 9033 Red Branch Road, Columbia, MD, United States, 21045
- Phone
- 443-367-5500
- Website
- hemagen.com
About Hemagen Diagnostics Inc
Hemagen Diagnostics, Inc. provides human and veterinary diagnostic services worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its proprietary test kits are used to aid in the diagnosis of certain autoimmune and infectious diseases. It also provides human diagnostics, such as universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and specialty assays, including Chagas, acute phase proteins, and cytokines. In addition, the company offers veterinary diagnostic products, such as equipment, reagents, supplies, accessories, and electrodes in chemistry, hematology, and electrolyte areas. Its products are used in laboratories, hospitals and blood banks. Hemagen Diagnostics, Inc. was incorporated in 1985 and is based in Columbia, Maryland.
Hemagen Diagnostics Inc management
2- Mr. William P. HalesExecutive Chairman, CEO & President · born 1962
- Mr. M. Robert CampbellCFO & COO · born 1970